CLINICAL STUDY

Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly

H E Turner 1, D R M Lindsell 2, A Vadivale 1, A V Thillainayagam 3 and J A H Wass 1

Departments of 1 Endocrinology, Radcliffe Infirmary, Oxford, 2 Radiology, John Radcliffe Hospital, Oxford and 3 Gastroenterology, Charing Cross Hospital, London, UK

(Correspondence should be addressed to J A H Wass, Department of Endocrinology, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK)

Abstract

Background: Octreotide treatment may be associated with gall stone development in up to 50% of patients with acromegaly. Two new sustained-release formulations of somatostatin analogue have been recently developed: lanreotide SR (Somatuline) and octreotide LAR (Sandostatin LAR). The incidence of gall-stone development in patients receiving these drugs has been shown to be less than 20%, but the duration of follow-up has been limited.

Objective: Prospectively to assess and compare the effects of the two new long-acting somatostatin agonists on gall bladder motility in patients with acromegaly.

Method and patients: Eleven patients with active acromegaly were studied. Three patients had asymptomatic gall stones at the start of the study. Ultrasound scans were performed before commencement of the treatment, and repeated during treatment with lanreotide SR and octreotide LAR. The presence of gall stones, fasting gall bladder volume (FV), residual volume (RV) and maximal percentage gall bladder emptying were measured.

Results: One patient developed asymptomatic small gall stones after treatment with octreotide LAR for 4 months. FV and RV were both significantly larger when patients received treatment with lanreotide SR or octreotide LAR compared with pretreatment values ($P<0.05$ for both). Maximal percentage gall bladder emptying was significantly reduced in patients receiving lanreotide SR or octreotide LAR compared with pretreatment ($P<0.01$), but was less impaired in patients receiving lanreotide SR than in those receiving octreotide LAR ($P<0.01$).

Conclusions: Gall bladder motility is impaired in patients receiving either of these new long-acting preparations, and long-term follow-up will be needed to establish the true incidence of gall stones.

Introduction

The somatostatin analogue, octreotide, has been used to treat acromegaly for more than 10 years (1). Two new sustained-release formulations of somatostatin analogue have recently been developed: lanreotide SR (Somatuline) and octreotide LAR (Sandostatin LAR). In contrast to thrice daily subcutaneous administration, these drugs need to be administered only every 7–14 days or every 28 days, respectively. They have both been shown to provide effective growth hormone-lowering treatment for patients with acromegaly (2–8).

It has been recognised for many years that octreotide treatment may be associated with the development of gall stones in up to 50% of patients with acromegaly (9, 10) and also in patients with other conditions such as carcinoid and islet cell tumours (11). These gall stones are usually asymptomatic and only rarely need definitive management (12). Gall-stone prevalence in the general population ranges from approximately 10 to 25%.

The mechanism of development of octreotide-induced gall stones is related, at least in part, to inhibition of cholecystokinin (CCK) secretion and reduced gall bladder emptying (13–15), in addition to prolonged large-bowel transit times (15). It has been clearly demonstrated that octreotide leads both to suppression of cholecystokinin secretion (16, 17) and to decreased sensitivity to cholecystokinin (18, 19). In addition, octreotide produces lithogenic changes in bile composition, leading to increased deoxycholic acid conjugates and cholesterol saturation of gall-bladder bile (12, 15, 20). Marked reductions in gall bladder emptying have been demonstrated in patients receiving octreotide treatment, both acutely and with prolonged treatment (13–15).

Treatment with ursodiol has been shown to reverse the abnormalities in some patients with acromegaly who are receiving octreotide (21–23). It has been suggested that timing octreotide injections in relation to meals (24), or periodic breaks in treatment may reduce the incidence of gall-stones (12, 25). Gall-bladder...
contractility has been shown to return to normal within 2 weeks of discontinuation of octreotide treatment (26).

There have been some studies of the effectiveness of both octreotide LAR and lanreotide SR in patients with acromegaly that showed that gall-bladder abnormalities, including gall stones, were associated with these drugs, but that their incidence was low (<20%) (27), and it has been suggested that the incidence of gall stones in patients receiving these newer, long-acting somatostatin analogues may be lower. A study comparing treatment with continuous subcutaneous infusion of octreotide and treatment by intermittent subcutaneous doses demonstrated that octreotide injections led to impaired gall-bladder contraction for at least 4 h, but that cholecystokinin release was normal 8 h after an injection, whereas, although gall bladder contraction was less impaired during continuous subcutaneous octreotide treatment, CCK concentrations remained very low (24). Thus it might be expected that continual exposure to lower somatostatin concentrations may be associated with less impairment of gall-bladder motility.

There have been no previously reported studies assessing the effect of these long-acting preparations on gall-bladder motility or comparing the effects of the two drugs on gall bladder in the same patients.

The aim of this study was prospectively to assess and compare the effects of the two new long-acting somatostatin agonists on gall-bladder motility in patients with acromegaly.

Patients and methods

Patients

We studied 11 patients (Table 1) (mean age 59.6 years, range 45–71 years, five women) with active acromegaly (mean duration 6.6 years) as defined by clinical features and failure of circulating growth hormone (GH) concentrations to suppress below 2 mU/l after a 75 g oral glucose load. Three patients had gall stones at the start of the study, all of whom had been receiving prior octreotide treatment for a mean of 4 years (range 1–7 years). No patient had required any therapeutic intervention for cholelithiasis. Patients receiving subcutaneous octreotide (n = 4) underwent a washout period of at least 2 weeks before commencing the study protocol. The other patients had not previously been treated with somatostatin agonists. The study procedure was approved by the local research and ethics committee, and all patients gave their written informed consent to participate.

Study protocol

Ultrasound scans of the gall bladder were performed in all but one patient before the commencement of long-acting somatostatin analogue treatment. In six patients, the scans were repeated (midway between injections) after at least 4 months treatment with lanreotide SR. Four patients were receiving injections every 10 days; three received them every 7 days. These patients then had their treatment changed (after a washout period of at least 6 weeks) to octreotide LAR, and ultrasound scans performed after at least 4 months treatment with octreotide LAR. Four patients received octreotide LAR only and had scans performed at baseline and after at least 4 months treatment with octreotide LAR. Seven patients received 20 mg octreotide LAR and four patients received 30 mg.

The ultrasound scans were performed at 0800 h by a single observer (D R M L) without knowledge of the treatment, using a V328, 3.5 MHz sector transducer on an Acuson XP10 machine. The presence of gall stones was noted. The fasting volume (FV) of the gall bladder was calculated using the measurements of the length (l), height (h) and width (w) of the gall bladder (V = π / 6 × lwh) (13). These measurements were repeated 20 and 40 min after the patient had ingested 250 ml Ensure (Abbott Laboratories, Maidenhead, Berks, UK) and the smallest gall bladder volume determined (residual

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (yr)</th>
<th>Sex</th>
<th>Year of diagnosis</th>
<th>Previous octreotide† (years)</th>
<th>Gallstones at baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Presence</td>
</tr>
<tr>
<td>1</td>
<td>60</td>
<td>F</td>
<td>1988</td>
<td>7</td>
<td>+</td>
</tr>
<tr>
<td>2</td>
<td>71</td>
<td>M</td>
<td>1995</td>
<td></td>
<td>–</td>
</tr>
<tr>
<td>3</td>
<td>69</td>
<td>M</td>
<td>1978</td>
<td></td>
<td>–</td>
</tr>
<tr>
<td>4</td>
<td>44</td>
<td>M</td>
<td>1989</td>
<td>1</td>
<td>+</td>
</tr>
<tr>
<td>5</td>
<td>55</td>
<td>M</td>
<td>1990</td>
<td>4</td>
<td>+</td>
</tr>
<tr>
<td>6</td>
<td>51</td>
<td>F</td>
<td>1986</td>
<td></td>
<td>–</td>
</tr>
<tr>
<td>7</td>
<td>70</td>
<td>F</td>
<td>1992</td>
<td>0.5</td>
<td>–</td>
</tr>
<tr>
<td>8</td>
<td>52</td>
<td>F</td>
<td>1996</td>
<td></td>
<td>–</td>
</tr>
<tr>
<td>9</td>
<td>60</td>
<td>F</td>
<td>1996</td>
<td></td>
<td>–</td>
</tr>
<tr>
<td>10</td>
<td>71</td>
<td>F</td>
<td>1991</td>
<td></td>
<td>–</td>
</tr>
<tr>
<td>11</td>
<td>53</td>
<td>M</td>
<td>1986</td>
<td></td>
<td>–</td>
</tr>
</tbody>
</table>

† Duration of previous treatment.
+ , gallstones present; –, no gallstones.
volume, RV). The maximal percentage gall bladder emptying was calculated from the formula $1 - \frac{RV}{FV} \times 100$ (13).

**Statistical analysis**

Wilcoxon’s rank sum test was used to compare the two groups. A value of $P < 0.05$ was chosen to represent statistical significance.

**Results**

Three patients had gall stones before starting long-acting somatostatin analogue treatment. All three had received prior treatment with subcutaneous octreotide for a mean of 4 years (range 1–7 years). The ultrasound appearance of the stones did not change significantly during the course of the study period. A further patient developed asymptomatic small gall stones after treatment with octreotide LAR for 4 months.

Fasting gall-bladder volumes were significantly greater when patients were receiving treatment with either lanreotide SR or octreotide LAR, compared with the pretreatment ultrasound scans ($P < 0.05$ for both; Table 2). There was no difference between fasting gall-bladder volumes in patients receiving either drug. The gall bladder residual volumes were significantly greater compared with pretreatment values when patients were treated with either drug ($P < 0.01$ for both drugs; Fig. 1). There was no difference between the residual volumes in patients receiving either of the two drugs.

Maximal percentage gall bladder emptying was significantly reduced when patients received lanreotide SR or octreotide LAR compared with the pretreatment scans ($P < 0.01$ for both; Fig. 1). There was no difference in fasting or residual gall-bladder volumes or maximal gall-bladder emptying when patients with gall stones were compared with those without. Maximal gall bladder emptying was significantly less when patients were receiving octreotide LAR than in those treated with lanreotide SR ($P < 0.01$).

**Discussion**

This study clearly demonstrates that gall-bladder emptying is impaired in patients with acromegaly receiving treatment with either of the new long-acting somatostatin analogues. This is similar to the effects of the shorter-acting somatostatin analogue, octreotide. In addition, the fasting gall-bladder volumes were significantly greater when patients were receiving long-acting somatostatin agonist treatment. The greatly impaired gall-bladder contraction was further reflected in significantly larger gall-bladder residual volumes after the standard stimulation by ingestion of Ensure. As the duration of follow-up of patients treated with these newer long-acting analogues increases, the incidence of gall-stone development may be expected to rise, although the proportion of patients with gall stones who are symptomatic is likely to remain small.

The significantly more marked impairment of gall-bladder contractility in patients receiving treatment with octreotide LAR compared with those taking lanreotide SR may be related to overall drug effectiveness. Trough concentrations of 1.13 ng/ml for lanreotide SR and 1.3 ng/ml for octreotide LAR are very similar (2, 3) and, clearly, differences in effects of each drug will also depend on potency at receptor subtypes. Recent data from our unit suggest that, although there is no overall difference in proportion of patients who achieve a mean GH below a target of 5 mU/l, the overall mean GH is significantly lower when patients receive treatment with octreotide LAR compared with those taking lanreotide SR may be related to overall drug effectiveness. Trough concentrations of 1.13 ng/ml for lanreotide SR and 1.3 ng/ml for octreotide LAR are very similar (2, 3) and, clearly, differences in effects of each drug will also depend on potency at receptor subtypes.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Baseline FV (ml)</th>
<th>Lanreotide SR RV20 (ml)</th>
<th>Octreotide LAR RV20 (ml)</th>
<th>E (%)</th>
<th>Lanreotide SR RV40 (ml)</th>
<th>Octreotide LAR RV40 (ml)</th>
<th>E (%)</th>
<th>Lanreotide SR E</th>
<th>Octreotide LAR E</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>54</td>
<td>89</td>
<td>97</td>
<td>62</td>
<td>89</td>
<td>97</td>
<td>62</td>
<td>89</td>
<td>97</td>
</tr>
<tr>
<td>2</td>
<td>60</td>
<td>97</td>
<td>70</td>
<td>82</td>
<td>97</td>
<td>70</td>
<td>82</td>
<td>97</td>
<td>70</td>
</tr>
<tr>
<td>3</td>
<td>16</td>
<td>15</td>
<td>3.5</td>
<td>76</td>
<td>15</td>
<td>3.5</td>
<td>76</td>
<td>15</td>
<td>3.5</td>
</tr>
<tr>
<td>4</td>
<td>10.5</td>
<td>15</td>
<td>8.5</td>
<td>45</td>
<td>15</td>
<td>8.5</td>
<td>45</td>
<td>15</td>
<td>8.5</td>
</tr>
<tr>
<td>5</td>
<td>66</td>
<td>73</td>
<td>44</td>
<td>65</td>
<td>73</td>
<td>44</td>
<td>65</td>
<td>73</td>
<td>44</td>
</tr>
<tr>
<td>6</td>
<td>50</td>
<td>34</td>
<td>14</td>
<td>58</td>
<td>34</td>
<td>14</td>
<td>58</td>
<td>34</td>
<td>14</td>
</tr>
<tr>
<td>7</td>
<td>50</td>
<td>34</td>
<td>27</td>
<td>69</td>
<td>34</td>
<td>27</td>
<td>69</td>
<td>34</td>
<td>27</td>
</tr>
<tr>
<td>8</td>
<td>26</td>
<td>26</td>
<td>6.6</td>
<td>0</td>
<td>26</td>
<td>6.6</td>
<td>0</td>
<td>26</td>
<td>6.6</td>
</tr>
<tr>
<td>9</td>
<td>32</td>
<td>32</td>
<td>5.1</td>
<td>0</td>
<td>32</td>
<td>5.1</td>
<td>0</td>
<td>32</td>
<td>5.1</td>
</tr>
<tr>
<td>10</td>
<td>36</td>
<td>36</td>
<td>15</td>
<td>75</td>
<td>36</td>
<td>15</td>
<td>75</td>
<td>36</td>
<td>15</td>
</tr>
<tr>
<td>11</td>
<td>40</td>
<td>40</td>
<td>15</td>
<td>63</td>
<td>40</td>
<td>15</td>
<td>63</td>
<td>40</td>
<td>15</td>
</tr>
</tbody>
</table>

FV, fasting gall-bladder volume; RV20, gall-bladder volume 20 min after Ensure; RV40, gall-bladder volume 40 min after Ensure; E, maximal gall-bladder emptying, calculated as $1 - \frac{RV}{FV} \times 100$. 
biliary abnormalities, may be less likely to develop further stones if receiving lanreotide SR.

Further long-term data are required on the incidence of gall stones in patients receiving treatment with either of these drugs. The increased convenience of depot preparations and the awareness of the importance of control of GH concentrations in acromegaly are likely to lead to increasing numbers of patients with acromegaly receiving treatment with these drugs. The potential complication of gall-stone development should not be forgotten, and patients should be monitored for this potential complication of treatment, although the likelihood of symptomatic cholelithiasis should remain low.

Acknowledgements
We thank Ipsen Limited and Novartis Pharmaceuticals for providing the drugs.

References
17 Hopman WP, Van Liessum PA, Pieters GF, Jansen JB, Lamers CB, Smals AG et al. Postprandial gallbladder motility and plasma...

Received 9 March 1999
Accepted 12 August 1999